Health Care & Insurance  September 3, 2019

Brickell Biotech closes Vical merger, makes Nasdaq debut

By

BOULDER  — Brickell Biotech Inc. (Nasdaq: BBI) completed its reverse stock split and merger with San Diego-based Vical Inc., allowing it to list on the Nasdaq exchange.

The Boulder pharmaceutical company will eschew Vical’s gene-therapy focus and use its resources to work solely on therapies for skin conditions, according to filings with the U.S. Securities and Exchange Commission.

Brickell’s primary drug candidate is sofpironium bromide, a topical treatment for excessive sweating. The drug is registered to begin two separate Phase III trials with the U.S. Food and Drug Administration, both expected to begin in the fourth…

Related Posts

Ken Amundson is managing editor of BizWest. He has lived in Loveland and reported on issues in the region since 1987. Prior to Colorado, he reported and edited for news organizations in Minnesota and Iowa. He's a parent of two and grandparent of four, all of whom make their homes on the Front Range. A news junkie at heart, he also enjoys competitive sports, especially the Rapids.
Categories: Automotive Boulder Health Care & Insurance M&A
Sign up for BizWest Daily Alerts
Closing in 8 seconds...